ArticleWorld journal of nuclear medicine

Everolimus-induced somatostatin receptor overexpression in a rectal neuroendocrine tumor patient may promote somatostatin receptor-guided radionuclide therapy (peptide receptor radiotherapy) as an additional treatment option.

Magdalena Mileva et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.